Ashland Global (ASH)
NYSEMaterialsChemicals - SpecialtySnapshot 2026-09-04
NYSEMaterialsChemicals - SpecialtySnapshot 2026-09-04
Research Workspace
Put ASH beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Materials: fringe margins under pressure (0q confirmed)
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Management is running behind on a stated commitment.
View ThesisRevenue is contracting — down about 1% over the past year.
View GrowthRanks among the strongest in its industry on quality — around the top 21%.
View QualityMiddle-of-the-pack management execution.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskASH's growth depends on advancing its global innovation strategies and achieving revenue targets. Revenue grew 7% year over year, but the latest earnings report missed expectations. It trades at 22× P/E versus a peer median of 18×, suggesting modest growth is priced in. The risk lies in management falling behind on commitments, as indicated by the recent earnings miss and a 32% probability of missing again. Peer multiples imply a price roughly in line with where it trades (about fair). Our read remains intact.
Trailing returns as of 2026-09-04. ASH is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 12 analysts currently covering ASH (as of Sep 2026).
Based on 6 Wall Street analysts offering 12-month price targets for ASH in the last 4 months.
Continue this research
Compare ASH with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| ASH Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 4 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Diversified Chemicals — fair value, gap to price, and forward P/E.
Compare the value case
Put ASH next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Advance globalize and innovate strategies
New product aligns with innovation strategy and growth objectives.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-04. EPS is implied from price ÷ P/E. Not investment advice.
Current $72.93
The last 12 months of price, then the range of analyst 12-month targets from today’s $72.93.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.

Activist pressure may lead to strategic improvements.

Advances: Achieve $1,835-$1,870M revenue in fiscal 2026
Earnings beat supports revenue growth objective.
